Published online May 15, 2024. doi: 10.4251/wjgo.v16.i5.2006
Peer-review started: September 13, 2023
First decision: December 14, 2023
Revised: January 10, 2024
Accepted: March 18, 2024
Article in press: March 18, 2024
Published online: May 15, 2024
Processing time: 239 Days and 12.1 Hours
N6-methyladenosine (m6A) modification represents the predominant alteration found in eukaryotic messenger RNA and plays a crucial role in the progression of various tumors. However, despite its significance, the comprehensive investigation of METTL5, a key m6A methyltransferase, in colorectal cancer (CRC) remains limited.
To investigate the role of METTL5 in CRC.
We assessed METTL5 expression levels in clinical samples obtained from CRC patients as well as in CRC cell lines. To elucidate the downstream targets of METTL5, we performed RNA-sequencing analysis coupled with correlation analysis, leading us to identify Toll-like receptor 8 (TLR8) as a potential downstream target. In vitro functional assessments of METTL5 and TLR8 were conducted using CCK-8 assays, scratch assays, as well as assays measuring cell migration and invasion.
Our findings reveal a pronounced upregulation of METTL5 expression in both CRC cells and tissues, which correlated significantly with an unfavorable prognosis. In vitro experiments unequivocally demonstrated the oncogenic role of METTL5, as evidenced by its promotion of CRC cell proliferation, invasion, and migration. Notably, we identified TLR8 as a downstream target of METTL5, and subsequent down-regulation of TLR8 led to a significant inhibition of CRC cell proliferation, invasion, and tumor growth.
The heightened expression of METTL5 in CRC is strongly associated with clinicopathological features and a poor prognosis, thereby underscoring its potential utility as a critical marker for facilitating early diagnosis and prognostication in CRC.
Core Tip: N6-methyladenosine is one of the most common post-transcriptional RNA modifications in mammals and one of the major methylation modifications in mRNA and non-coding RNAs, which can affect RNA splicing, translation, stability, and epigenetic effects of certain non-coding RNAs. This is the first fundamental study to examine the role of METTL5 in colorectal cancer (CRC), which is important for understanding the impact of the METTL family on the development of CRC.
